Increased vascular permeability facilitates metastasis. Emerging evidence indicates that secreted microRNAs (miRNAs) may mediate the crosstalk between cancer and stromal cells. To date, whether and how secreted miRNAs affect vascular permeability remains unclear. Based on deep sequencing and quantitative PCR, we found that higher level of serum miR-103 was associated with higher metastasis potential of hepatocellular carcinoma (HCC). The in vitro endothelial permeability and transendothelial invasion assays revealed that the conditioned media or exosomes derived from high miR-103-expressing hepatoma cells increased the permeability of endothelial monolayers, but this effect was attenuated if exosome secretion of hepatoma cells was blocked by silencing ALIX and HRS or if miR-103 within hepatoma or endothelial cells was antagonized. Most importantly, pretreating endothelial monolayers with exosomes that were from stable miR-103-expressing hepatoma cells facilitated the transendothelial invasion of tumor cells, and this role of exosomes was abrogated by inhibiting miR-103 in endothelial cells. Further in vivo analyses disclosed that mice with xenografts of stable miR-103-expressing hepatoma cells exhibited higher vascular permeability in tumor, higher level of exosomal miR-103 and greater number of tumor cells in blood circulation, and increased rates of hepatic and pulmonary metastases, compared to control mice. Mechanism investigations revealed that hepatoma cell-secreted miR-103 could be delivered into endothelial cells via exosomes, and then attenuated the endothelial junction integrity by directly inhibiting the expression of VE-Cadherin (VE-Cad), p120-catenin (p120) and zonula occludens 1. Moreover, miR-103 could also promote tumor cell migration by repressing p120 expression in hepatoma cells. Conclusion: Hepatoma cell-secreted exosomal miR-103 increases vascular permeability and promotes tumor metastasis by targeting multiple endothelial junction proteins, which highlights secreted miR-103 as a potential therapeutic target and a predictive marker for HCC metastasis. (HEPATOLOGY C ancer metastasis is a complex, multi-step process in which tumor cells detach from the primary site, migrate and invade the extracellular matrix, intravasate into vessels, survive in the bloodstream, extravasate from vessels, seed in target organ and grow to form metastatic nodules.
C
ancer metastasis is a complex, multi-step process in which tumor cells detach from the primary site, migrate and invade the extracellular matrix, intravasate into vessels, survive in the bloodstream, extravasate from vessels, seed in target organ and grow to form metastatic nodules. (1, 2) Much progress has been made in exploring the mechanisms that confer tumor cells with the ability to detach, migrate and invade, but less attention is paid to the mechanisms that regulate vascular permeability and thereby affect metastasis. Traversing of tumor cells through vascular barrier is a crucial step in metastasis
Abbreviations: 3 0 -UTR, 3 0 -untranslated region; CM, conditioned medium; DMEM, Dulbecco's modified Eagle's medium; E-Cad, E-Cadherin; HCC, hepatocellular carcinoma; HUVECs, Human umbilical vein endothelial cells; miRNA, microRNA; MVD, microvessel density; p120, p120-catenin; NC, negative control; qPCR, real-time quantitative PCR; rhodamine-dextran, rhodamine B isothiocyanate-dextran; SFM, serum free medium for endothelial cell; VE-Cad, VE-Cadherin; ZO-1, zonula occludens 1. process. (1, (3) (4) (5) Cell-to-cell junctions between endothelial cells, which are critical in maintaining vascular integrity, consist of adherens junctions and tight junctions. The endothelial adherens junction complex comprises VE-Cad and catenins (p120-, p0071-and b-catenin), while zonula occludens 1 (ZO-1) and claudin-5 are central components of the tight junctions. (6) Loss of these membrane-associated adhesion molecules will attenuate the endothelial junction integrity and increase vascular permeability, consequently destroy vascular barrier and facilitate metastasis of cancer cells. (3) (4) (5) To date, several tumor cell-secreted proteins, such as VEGF, angiopoietin-2 and thrombin, have been demonstrated to regulate the expression of these adhesion molecules. (7) (8) (9) MicroRNAs (miRNAs) belong to a class of small noncoding RNAs, modulate gene expression posttranscriptionally and regulate various cell activities. (10) Dysfunction of miRNAs is implicated in different pathological processes, especially in cancer development. (11) Emerging evidence shows that miRNAs can be actively secreted and delivered into recipient cells, where they block the translation of target genes and thereby affect the activities of recipient cells. (12) (13) (14) (15) Thus, secreted miRNAs may serve as a class of signaling molecules in cell-to-cell communication. It has been shown that cancer-secreted miRNAs play a crucial role in regulating the proliferation of tumor cells, activation of tumor-associated immune cells and growth of tumor vessels. (14) (15) (16) (17) However, whether and how secreted miRNAs affect the endothelial junction integrity and vascular barrier function remain unclear. To date, only one study employed both in vitro and in vivo models to analyze the effect of cancer cellsecreted miRNA on vascular permeability. The authors showed that breast cancer-secreted miR-105 could be delivered into endothelial cells, reduced ZO-1 expression, and attenuated the endothelial junction integrity and promoted metastasis. (3) Therefore, more extensive investigations in this field are required.
Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis. To date, a few studies have revealed that the intercellular transfer of exosomal miRNAs modulate the growth, migration and chemosensitivity of HCC cells. (14, (18) (19) (20) However, these studies only provide in vitro evidence and mainly focus on the intercellular communication between HCC cells. In an attempt to identify tumor cell-secreted miRNAs that promote cancer metastasis by destroying endothelial junction integrity, we disclosed that hepatoma cellsecreted miR-103 could be delivered into endothelial cells and inhibited the expression of VE-Cad, p120-catenin (p120) and ZO-1, which abrogated endothelial junction integrity and consequently promoted tumor metastasis. Furthermore, an increase of miR-103 level in the circulation was correlated with increase of metastasis and recurrence in HCC patients. These data highlight the importance of cancer cell-secreted miRNAs in regulating tumor vessel integrity and cancer metastasis and provide a biomarker and therapeutic target for HCC metastasis.
Materials and Methods
More details are provided in Supporting Materials and Methods.
PATIENTS AND SPECIMENS
All blood samples were obtained from pathologicallyconfirmed HCC patients who underwent HCC resection at the Cancer Center, Sun Yat-sen University. The relevant characteristics of patients are summarized in Supporting Tables S1 and S2 .
SOLEXA SEQUENCING
Solexa sequencing analysis was performed by BGI (Shenzhen, China).
RNA OLIGORIBONUCLEOTIDES AND VECTORS
We used miR-103 mimics and miR-103 inhibitor (Anti-miR-103), and their negative control (NC and Anti-NC, respectively), FITC-labeled miR-103, siA-LIX and siHRS, in this study.
The lentiviral vector pCDH-miR-103, which expressed miR-103, was generated based on pCDH-CMV-MCS-EF1-copGFP vector (System Biosciences, Mountain View, CA), a lentiviral vector that expressed fluorescent copGFP and was designated as pCDH-Ctrl in this study.
Firefly luciferase reporter system was used to verify whether the 3 0 -untranslated region (3 0 -UTR) of VECad, p120 and ZO-1 mRNA was targeted by miR-103.
All constructs were verified by direct DNA sequencing. The sequences of DNA oligoribonucleotides are provided in Supporting Table S3 .
CELL LINES AND CELL CULTURE
Hepatoma cell lines (QGY-7703, HepG2, MHCC97H), immortalized human liver cell line (LO2) and transformed human embryonic kidney cell line (HEK293T) were maintained in Dulbecco's modified Eagle's medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 100 U/mL penicillin and 100 lg/mL streptomycin in a humidified atmosphere of 5% CO 2 at 378C. The FBS used for conditioned medium (CM) collection, exosome isolation and endothelial cell treatment was depleted of exosomes by overnight centrifugation at 100,000g, 4 o C, as reported. (3) The following sublines were established by infecting cells with lentivirus pCDH-miR-103 or pCDH-Ctrl: the QGY-7703, HepG2 and LO2 sublines which stably expressed miR-103 (named as QGY-miR-103, G2-miR-103, LO2-miR-103) and their matched control lines (QGY-Ctrl, G2-Ctrl, LO2-Ctrl). All these sublines expressed copGFP.
Human umbilical vein endothelial cells (HUVECs), normal liver sinusoidal endothelial cells (LSECs), and an endothelial cell line Sk-Hep-1 that was derived from hepatic ascites adenocarcinoma were used as endothelial cells for in vitro studies. HUVECs were isolated as described. (21) LSECs and SK-Hep-1 cells were purchased from Icellbioscience (Shanghai, China) and ATCC (Manassas, VA), respectively.
CELL TRANSFECTIONS
Reverse transfection of RNA duplex (50 nM) or miRNA inhibitor (100 nM) was performed with Lipofectamine RNAiMAX (Life Technologies). Cotransfection of RNA duplex with plasmid DNA was conducted using Lipofectamine 2000 (Life Technologies).
PREPARATION OF THE CM
The CM from the liver cells or hepatoma cells that were grown in serum-free medium for endothelial cell ([SFM] Life Technologies) supplemented with 10% exosome-depleted FBS (10% FBS-containing SFM) was collected and stored at -808C. For incubating with HUVECs, the collected CM was resupplemented with 10% exosome-depleted FBS.
ISOLATION, CHARACTERIZATION AND QUANTIFICATION OF EXOSOMES
The exosomes from the CM of liver cells or hepatoma cells that were grown in DMEM supplemented with 10% exosome-depleted FBS (10% FBS-DMEM) were isolated, and characterized by using transmission electron microscope (JEM-100CX-II, JEOL, Japan), NanoSight analysis (NanoSight NS-300 instrument, Malvern, United Kingdom) and western blot. (22) At the time to collect CM, the number of cells was counted to allow appropriate correction of the volume of CM supplied to exosome isolation. The protein concentration of the harvested exosomes was then detected by bicinchoninic acid protein assay kit (BCA, Pierce Biotechnology, Inc., Rockford, IL) to correlate the number of cells with the yield of exosomes. For cell treatment, exosomes collected from 5310 6 cells (equivalent to 2 lg of exosomes) were added to 2310
CELLULAR INTERNALIZATION OF EXOSOMES
Exosomes were labeled with DiIC 16 (SigmaAldrich, St. Louis, MO), then resuspended in 10% exosome-depleted FBS-SFM, added to the HUVECs at 80% confluence, and incubated for 4 hours before imaging under a fluorescence microscope.
RNA ISOLATION
Isolation of cellular or extracellular RNA was performed using TRIzol reagent (Life Technologies). Prior to isolation of extracellular RNA (serum, plasma, CM or exosomes), a C. elegans miRNA, cel-miR-67, was spiked into the samples (final concentration: 0.2 nM) and used as a reference as reported. (23) During isopropanol precipitation, glycogen (Ambion/Applied Biosystems, Foster City, CA) was added as a coprecipitant (final concentration: 100 lg/mL) to enhance the yield of extracellular RNA.
ANALYSIS OF GENE EXPRESSION
The expression level of target genes was assessed by semiquantitative RT-PCR, real-time quantitative PCR (qPCR), western blot or immunofluorescent staining. The primers used for PCR are provided in Supporting Table S3 .
IN VITRO ENDOTHELIAL PERMEABILITY ASSAY
The in vitro endothelial permeability was assessed by quantifying the amount of rhodamine B isothiocyanatedextran (rhodamine-dextran, average MW 70,000; Sigma-Aldrich) that passed through the endothelial monolayers without or with CM or exosome treatment.
TRANSENDOTHELIAL INVASION ASSAY
Transendothelial invasion assay was performed to detect the GFP-expressing hepatoma cells that invaded through HUVEC monolayers without or with exosome treatment. QGY-Ctrl or QGY-miR-103 cells were inoculated under the capsule of the left hepatic lobe of male BALB/c nude mice at 5 weeks of age. Five weeks later, the xenografted mice were then applied to in vivo vascular permeability analysis, detection of the circulating tumor cells and miR-103 in the blood, and evaluation of metastasis, MMP2 expression and microvessel density (MVD) of xenografts.
MOUSE STUDIES
For in vivo vascular permeability analysis, two assays were performed using rhodamine-dextran and Evans Blue.
To detect the circulating QGY-Ctrl/QGY-miR-103 cells and miR-103 in the blood of tumor-bearing mice, 500 ul blood was collected in tubes with EDTA and subjected to centrifugation to isolate cells from plasma. The plasma was then subjected to sequential centrifugation to discard cell debris. Exosomes were further isolated from plasma by the Total Exosome Isolation Kit (from plasma, Life Technologies). The RNA was then extracted from exosomes, plasma or cells using TRIzol. We applied qPCR to analyze miR-103 levels in exosomes and plasma, and the mRNA level of GFP in cells that indicated the number of circulating QGY-Ctrl or QGY-miR-103 cells in the blood.
To evaluate the metastasis, serial sections from the lungs and the livers excluding the lobe with primary tumor were stained with hematoxylin-eosin (HE) and screened for metastatic nodules. Meanwhile, xenograft sections were applied to immunohistochemical staining for murine CD34 (clone MEC14.7, BioLegend, San Diego, CA), an endothelial cell marker, and for MMP2 (Chemicon, Te-mecula, CA), a molecule that promotes tumor invasion. Any discrete cluster or single cell stained for CD34 was counted as one microvessel as reported. (21) LUCIFERASE REPORTER ASSAY HEK293T cells in a 48-well plate were cotransfected with 10 nM of miR-103 or NC duplex, 2 ng of pRL-CMV (expressing Renilla luciferase), and 20 ng of firefly luciferase reporter plasmid that contained either wild-type or mutant 3 0 -UTR of target gene. Then 48 hours after transfection, cell lysates were applied to luciferase assay as described. (24) 
IN VITRO MIGRATION ASSAYS
We placed 8310 4 HepG2 cells or 5310 4 QGY-7703 cells in serum-free DMEM into the upper chamber of 24-well Boyden Chamber (8-lm pore size; Corning), while the lower chamber was filled with 600 ll 10% FBS-DMEM. After 10 hours of incubation, cells were fixed and stained with crystal violet as described. (21) All the migrated cells were counted.
STATISTICAL ANALYSIS
Data are expressed as the mean 6 standard error of the mean (SEM). Unless otherwise indicated, for all in vitro experiments, data from at least three independent experiments were analyzed. The differences between groups were analyzed using two Student t test when only two groups, or by one-way ANOVA when more than two groups were compared. All statistical tests were twosided. Differences were considered statistically significant at P < 0.05. All analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL).
Results

HEPATOMA CELL-SECRETED miR-103 INCREASES THE PERMEABILITY OF ENDOTHELIAL MONOLAYERS AND FACILITATES THE TRANSENDOTHELIAL INVASION OF TUMOR CELLS IN VITRO
To identify the secreted miRNAs that were associated with HCC progression, Solexa deep sequencing was used to detect small RNAs in the sera from HCC patients of long and short recurrence-free survival groups. We focused on miRNAs that had at least 1,000 copies in either group and identified 18 miRNAs that exhibited significantly differential levels between two survival groups (Fold change > 5, Supporting Table S4 ). Among them, hsa-miR-103a-3p (miR-103) is the most abundant miRNA in the serum of short survival group (Supporting Table S4 ). A higher level of serum miR-103 was significantly associated with higher metastasis potential, higher TNM stage (Supporting Table S2 ) and higher recurrence risk of HCC (Fig. 1A) . Both univariate and multivariate analyses also revealed that a high level of serum miR-103 was an independent predictor for short recurrence-free survival of HCC patients (Table 1) . Furthermore, cellular miR-103 and secreted miR-103 were detected at relatively high levels in two metastatic hepatoma cell lines (MHCC97H and QGY-7703), (25, 26) at low levels in nonmetastatic HepG2 cells, and immortalized liver cell line LO2, (25, 27) and at extremely low level in HUVECs (Fig. 1B) . These data prompted us to explore the effect of hepatomasecreted miR-103 on HCC metastasis.
Active angiogenesis and increased vascular permeability are critical factors that facilitate tumor metastasis. (1) We therefore explored whether hepatoma cells secreted miR-103 via exosomes and then affected endothelial permeability. First, the extracellular vesicles that were harvested from the conditioned media (CM) of different cells were characterized as exosomes by using electron microscopy and NanoSight analysis to detect the size of vesicles (Supporting Fig. S1A ,B) and by using western blot to detect the exosomal membrane marker CD63 (Supporting Fig. S1C ). Next, in vitro endothelial permeability assay was performed to measure the traversing of rhodamine-labeled dextran through the monolayer of HUVECs that were nontreated or pretreated with exosomes or CM. As shown, pretreatment with QGY-7703 cell-derived exosomes allowed much more dextran to traverse through HUVEC monolayer ( Fig. 2A) , suggesting increased endothelial permeability. However, treatment with exosomes from LO2 or HepG2 cells, which displayed much lower secreted miR-103 level than QGY-7703 cells (Fig. 1B) , only marginally increased the transendothelial transport of dextran ( Fig. 2A) , whereas both exosomes and CM from stable miR-103-expressing LO2 or HepG2 cells (LO2-miR-103 or G2-miR-103, Supporting Fig. S2A , B) could significantly enhance the transendothelial transport of dextran ( Fig. 2B; Supporting Fig. S3A ). On the other hand, the effect of QGY-7703-derived exosomes or CM to enhance the transendothelial transport of dextran was abrogated, if exosome secretion of QGY-7703 cells was blocked by silencing ALIX and HRS (Fig. 2C) or when miR-103 within QGY-7703 cells ( Fig. 2C; Supporting Fig. S3B ) or HUVECs (Fig.  2D ) was antagonized by Anti-miR-103. These results were further verified using hepatic endothelial cell lines, including LSECs and SK-Hep-1 (Supporting Fig.  S3C,D) . Most importantly, transendothelial invasion assays revealed that much more hepatoma cells invaded through HUVEC monolayers that were pretreated with exosomes from HepG2-miR-103 or QGY-miR-103 cells, compared with those monolayers treated with exosomes from the control cells without stable miR-103 expression (Supporting Fig. S2B,C, Fig. 2E ). And this enhanced transendothelial invasion resulted from treatment of HUVEC monolayers with QGY-miR-103-derived exosomes was attenuated by antagonizing miR-103 within HUVECs (Fig. 2F) . On the other hand, although CM from Anti-NCtransfected QGY-7703 cells enhanced the tube formation of HUVECs, this enhancement was not affected by inhibiting miR-103 in QGY-7703 cells (Supporting Fig. S4 ), suggesting that hepatoma cell-secreted miR-103 has no effect on tubulogenesis.
These in vitro data indicate that hepatoma cellsecreted exosomal miR-103 may increase the For (E-F), GFPexpressing QGY-Ctrl cells were added to the top of pretreated HUVEC monolayers that were grown on transwell inserts and incubated for another 12 hours. The GFP expressing cells that invaded through HUVEC monolayers to the lower surface of transwell inserts were then quantified under a fluorescent microscope. -, no exosomes were added to HUVECs; 1, the indicated exosomes were added to HUVECs. * P < 0.05, ** P < 0.01. Abbreviations: exo, exosomes; NC, negative control; ns, not significant. permeability of endothelial monolayers and facilitate the transendothelial invasion of hepatoma cells.
HEPATOMA CELL-SECRETED miR-103 INCREASES VASCULAR PERMEABILITY AND PROMOTES METASTASIS IN VIVO
We next demonstrated the effect of secreted miR-103 on vascular barriers and tumor metastasis in vivo. QGY-7703-miR-103 cell line and its control line were implanted into murine livers. Mice with QGY-miR-103-derived xenografts displayed much higher level of miR-103 in the plasma and in the exosomes from plasma, compared with QGY-Ctrl-xenograft bearing mice (Fig. 3A, Supporting Fig. S5A ).
To analyze the in vivo vascular permeability, fluorescent dextran or Evans Blue dye were intravenously injected into tumor-bearing mice. Compared with QGY-Ctrl-tumors, much more dextran (Fig. 3B) or Evans Blue dye (Fig. 3C) extravasated from blood circulation into QGY-miR-103-xenografts, indicating that the vasculatures in QGY-miR-103-xenografts exhibit higher permeability. Furthermore, mice bearing QGYmiR-103-xenografts displayed greater numbers of circulating tumor cells (Fig. 3D) , higher rates of hepatic and pulmonary metastases, and also showed more and larger metastatic nodules in both liver and lung (Fig. 3E-F) . However, the tumor volume (Supporting Fig. S5B ), the MVD (Supporting Fig. S5C ) and MMP2 expression (Supporting Fig. S5D ) of xenografts were similar between QGY-miR-103 and QGY-Ctrl groups.
These in vivo data support the conclusion that hepatoma cells may secrete high level of exosomal miR-103 to increase vascular permeability, weaken vascular barriers, and consequently, promote tumor metastasis.
HEPATOMA CELL-SECRETED EXOSOMAL miR-103 WAS DELIVERED INTO ENDOTHELIAL CELLS
We then examined whether hepatoma cell-secreted exosomal miR-103 could be delivered into endothelial cells and found that cellular level of mature miR-103 significantly increased in recipient HUVECs that were incubated with the exosomes or CM derived from QGY-7703 ( Fig. 4A ; Supporting S6A), which contained high level of miR-103 (Fig. 1B) and enhanced the traversing of dextran through HUVEC monolayers ( Fig. 2A; Supporting Fig. S3B ). However, miR-103 level was not increased in recipient HUVECs following treatment with exosomes or CM derived from LO2 or HepG2 cells ( Fig. 4A ; Supporting S6A), which displayed low miR-103 level (Fig. 1B) and could not affect the endothelial permeability ( Fig. 2A;  Supporting Fig. S3A ). Consistently, miR-103 level in recipient HUVECs significantly increased after HUVECs were incubated with the exosomes or CM of Anti-NC-transfected QGY-7703 cells ( Fig. 4B;  Supporting Fig. S6B ), but did not change if HUVECs were treated with exosomes or CM from Anti-miR-103-transfected QGY-7703 cells, which showed significantly reduced level of miR-103 (Supporting Fig.  S7 ) and had no effect on vascular permeability ( Fig.  2C; Supporting Fig. S3B ). Similar results were obtained when hepatic endothelial cell lines, LSECs and SK-Hep-1, were used as recipients (Supporting Fig. S8A,B) . We then excluded the possibility that hepatoma cell-derived CM induced the expression of endogenous miR-103 in HUVECs, because treatment with hepatoma cell-derived CM did not affect the level of pri-miR-103-A2 (one of the two primary miR-103 transcripts for mature miR-103) (Supporting Fig. S9 ) in HUVECs, and pri-miR-103-A1 was undetectable in both HUVECs and hepatoma cells (data not shown). These data suggest that increase of miR-103 in endothelial cells after treatment with hepatoma cellderived exosomes may result from transferring of extracellular miR-103 into endothelial cells.
We further explored whether exosomes mediated the transferring of miR-103 into endothelial cells. Firstly, knockdown of ALIX and HRS in QGY-7703 cells did not affect cellular miR-103 level but significantly reduced the miR-103 level in QGY-7703-derived CM and exosomes (Supporting Fig. S10) . Consistently, the increase of miR-103 level in recipient HUVECs by treatment of QGY-7703-derived exosomes or CM was attenuated if exosome secretion of QGY-7703 cells was blocked by silencing ALIX and HRS (Fig. 4C, Supporting Fig. S11 ). Next, exosomes from QGY-7703 cells that were transfected with FITC-tagged miR-103 were labeled with fluorescent dye DiIC 16 and then applied to treat HUVECs. As shown, both miR-103-FITC fluorescence and DiIC 16 -labeled exosomes were observed within recipient HUVECs (Fig. 4D, left panel) . As negative controls, no internalized FITC fluorescence or DiIC 16 was observed in the HUVECs that were incubated with nonlabeled exosomes (Fig. 4D, middle panel) or naked FITC-tagged miR-103 (Fig. 4D, right panel) . The metastases significantly increased in the mice bearing QGY-miR-103-xenografts. The rates of liver and lung metastasis, that is, the number of mice displaying liver or lung metastasis relative to the total number of tumor-bearing mice in each group, are indicated in the bottom of representative images (left panels; Scale bar, 100 lm). The number and maximal diameter of metastatic nodules in the livers and lungs of tumor-bearing mice are also showed (middle and right panels). For (A-F), 2310 6 QGY-Ctrl or QGY-miR-103 cells were inoculated into murine livers and metastasis was evaluated 5 weeks later. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: Met., metastasis rate; ns, not significant. These observations indicate that hepatoma cellsecreted exosomal miR-103 may be delivered into endothelial cells.
HEPATOMA CELL-SECRETED EXOSOMAL miR-103 ATTENUATES THE JUNCTION INTEGRITY OF ENDOTHELIAL CELLS BY TARGETING VE-Cad, p120 AND ZO-1
We next explored how secreted miR-103 attenuated the junction integrity of endothelial cells and increased vascular permeability. Putative targets of miR-103 were predicted using TargetScan and miRanda databases. Among the predicted targets, VE-Cad, p120 and ZO-1, which are important adherent molecules in maintaining endothelial cell-cell contacts, (6) were chosen for further validation. Immunofluorescence staining revealed that HUVEC monolayers treated with exosomes or CM from HepG2-miR-103 cells, but not from HepG2-control cells, exhibited a marked reduction of VE-Cad, p120 and ZO-1 expressions, indicating loss of contact between endothelial cells ( Fig. 5A;  Supporting Fig. S12A ). Furthermore, HUVEC monolayers treated with exosomes or CM from Anti-NC-transfected QGY-7703 cells, but not from AntimiR-103-transfected QGY-7703 cells, displayed reduced VE-Cad, p120 and ZO-1 expression (Fig.  5B, Supporting Fig. S12B ). Likewise, transfection of Anti-miR-103 into HUVECs significantly attenuated the capacity of QGY-7703-derived exosomes or CM to reduce the expression of these adhesion molecules (1) for 48 hours before immunofluorescence staining. VE-Cad (upper panels), p120 (middle panels) and ZO-1 (lower panels) were stained red, and cell nuclei were stained blue by DAPI. Scale bar, 25 lm. Abbreviation: Anti-NC, negative control for Anti-miR-103.
( Fig. 5C; Supporting Fig. S12C ). These results imply that hepatoma cell-secreted miR-103 may destroy endothelial adhesion junction integrity by reducing the expression of adhesion molecules.
The observation with immunofluorescence staining was then validated by western blot. Compared with HUVECs without treatment or treated with exosomes from LO2-or HepG2-control cells, those treated with exosomes from LO2-or HepG2-miR-103 displayed reduced protein levels of VE-Cad, p120 and ZO-1 (Fig. 6A,B) . Furthermore, treatment with QGYcontrol or QGY-miR-103-derived exosomes suppressed the expression of these adhesion molecules in HUVECs in a miR-103 dose-dependent manner (Fig.  6C) . Consistently, exosomes from Anti-miR-103-transfected QGY-7703 cells lost the activity to inhibit VE-Cad, p120 and ZO-1 in HUVECs, LSECs and SK-Hep-1 (Fig. 6D, Supporting Fig. S13A,B) . Moreover, transfection of Anti-miR-103 into HUVECs significantly abolished the capacity of QGY-7703-derived exosomes to decrease VE-Cad, p120 and ZO-1 expression in HUVECs (Fig. 6E) . As expected, incubation of HUVECs with hepatoma cell-derived CM exhibited the same effects as treatment with exosomes (Supporting Fig. S14A-D) . Lastly, a dualluciferase reporter assay revealed that cotransfection of miR-103 significantly inhibited the activity of firefly luciferase reporter carrying wild-type 3 0 -UTR of VECad, p120 or ZO-1, whereas this effect was abrogated when the predicted binding site in 3 0 -UTR was mutated (Fig. 6F) . These results suggest that hepatoma cell-secreted exosomal miR-103 may attenuate the endothelial adhesion junction integrity by directly targeting VE-Cad, p120 and ZO-1.
It is known that p120 stabilizes E-Cadherin (E-Cad)/b-catenin complex at cell membrane to maintain intercellular adhesion. (28, 29) Loss of p120 induces endocytosis of E-Cad and b-catenin. Cytoplasmic E-cad is then degraded, and b-catenin is degraded or phosphorylated and translocated into nuclear to induce transcription of downstream genes, (30) consequently promotes tumor metastasis. (2) We found that introduction of miR-103 in HepG2 and QGY-7703 cells diminished the expression of p120 and E-Cad proteins (Fig. 7A,B) , reduced the membrane-located b-catenin (Supporting Fig. S15 ) and promoted migration of these cells (Fig. 7C,D) . In contrast, antagonism of endogenous miR-103 upregulated the levels of p120 and E-Cad proteins (Fig. 7E ) and reduced cell migration (Fig. 7F) . These findings imply that high miR-103 expression in hepatoma cells may promote tumor migration by repressing p120 expression and in turn dissociating the adhesion junction complex.
Discussion
We disclosed that hepatoma cell-secreted miR-103 can be delivered into endothelial cells, then attenuate endothelial junction integrity and increase vascular permeability, and consequently promote tumor metastasis. Moreover, high level of serum miR-103 can serve as a noninvasive biomarker to predict metastatic potential and early recurrence of HCC. This work uncovers the function of secreted miR-103 and its clinical significance in HCC. Increased vascular permeability, a characteristic of tumor vessels, facilitates metastasis. (1, (3) (4) (5) The reason that tumor vessels displayed higher permeability is unclear. Increase of serum miR-103 has been detected in patients with colorectal or breast cancer. (31, 32) However, the function and regulatory network of secreted miR-103 remains unknown. Recent studies indicate that secreted miRNAs may mediate cancer cell-stromal cell crosstalk. (3, 12, 13, 16) Whether and how the cancer cellsecreted miRNAs affect vascular permeability remains unclear. Herein, we demonstrated that miR-103 was secreted by hepatoma cells via exosomes based on the following evidence: We then revealed that hepatoma cell-secreted exosomal miR-103 was delivered into endothelial cells, 0 -UTR. The luciferase activity of NC-transfectants from one of the experiments in WT group was set as 1. pRL-TK that expressed Renilla luciferase was used to correct the difference in transfection and harvest efficiencies. *P < 0.05. Abbreviations: Anti-NC, negative control for Anti-miR-103; NC, negative control for miR-103 duplex; ns, not significant. destroyed endothelial junction integrity and in turn enhanced tumor metastasis, based on the following findings from human clinical samples, cell and mouse models: These data not only reveal a paracrine effect of exosomal miR-103 and its underlying mechanism, but also identify serum miR-103 as a predictor for the metastasis and recurrence of HCC. Cell-to-cell junctions between endothelial cells, which are critical in maintaining vascular integrity, consist of adherens junctions and tight junctions. The endothelial adherens junction complex comprises VECad and catenins (p120-, p0071-and b-catenin), while ZO-1 is central components of the tight junctions. (1, 6) Molecules secreted by tumor cells, like VEGFA and angiopoietin 2, are able to abrogate the junction integrity and reduce the barrier property of endothelium by decreasing junction proteins. (7, 8) To date, only one study used both in vitro and in vivo models to disclose the effect of cancer cell-secreted miRNA on vascular permeability. They revealed that breast cancer-secreted miR-105 could be delivered into endothelial cells, then decreased ZO-1 expression and disrupted the endothelial junction integrity. (3) Herein, based on both gain-and loss-of function analyses, we revealed that hepatoma cell-secreted miR-103 was transferred into endothelial cells and in turn directly suppressed the expression of VE-Cad, p120 and ZO-1 by binding to the 3 0 -UTR of their mRNAs, consequently attenuated the endothelial junction integrity by simultaneously attenuating both adherens junctions and tight junctions.
To date, three studies based on both in vitro and in vivo models showed that miR-103 was upregulated in tumor tissues, and promoted metastasis by targeting Dicer, KLF4 and DAPK in breast cancer, gastric cancer and colorectal cancer. (33) (34) (35) In this study, we found that cellular miR-103 in hepatoma cells could repress the expression of p120, which can stabilize ECad at cell membrane by binding to the E-Cad and preventing E-Cad endocytosis and degradation. (2, (28) (29) (30) We showed that overexpression of miR-103 reduced p120 and E-Cad levels and promoted migration of hepatoma cells, whereas antagonism of endogenous miR-103 upregulated p120 and E-Cad proteins and suppressed cell migration. These results identify a miR-103-p120-E-Cad signaling pathway and its regulatory role in hepatoma migration.
The effect of cellular miR-103 on proliferation varies among different tumor cells. It was shown that miR-103 promoted proliferation of gastric cancer cells by targeting KLF4, (34) but suppressed proliferation of prostate cancer cells by targeting PDCD10. (36) We found that miR-103 did not significantly affect tumor growth, which was consistent with other studies in breast and colorectal cancers. (33, 35) The differential regulation of miR-103 on cell proliferation may be attributed to the difference in cell contexts.
To date, the function of secreted miR-103 on tumor angiogenesis has not been explored. We found that HUVECs treated with exosomes from QGY-7703 cells, which contained the high level of miR-103, displayed enhanced proliferation and migration, compared with HUVECs that were untreated or treated with LO2-or HepG2 -derived exosomes (Supporting Fig. S16) . Similarly, CM from Anti-NC-transfected QGY-7703 cells enhanced the tube formation of HUVECs (Supporting Fig. S4 , left and middle panels), However, this enhancement was not affected by inhibiting miR-103 in QGY-7703 cells (Supporting Fig. S4, right panel) . Moreover, QGY-miR-103 and QGY-Ctrl xenografts displayed similar MVD. These results indicate that secreted miR-103 may not regulate tumor angiogenesis. Collectively, this study revealed that the decreased endothelial barriers in a paracrine manner by secreted exosomal miR-103 and the enhanced cell migration by cellular miR-103 cooperate to confer hepatoma cells with a neat metastatic potential without affecting tumor growth and angiogenesis. Such a miRNA may represent a promising molecular target for antimetastasis therapy. Here we focused on exploring the paracrine effect of exosomal miR-103 and the function of cellular miR-103. It will be interesting to study the autocrine effect of exosomal miR-103 in future.
Blood-borne-metastasis is the leading cause of mortality in cancer patients. But little is known about the influence of secreted miRNA in the vascular barrier and tumor metastasis. In this study, we uncover the important role of hepatoma cell-secreted miR-103 on vascular integrity and tumor metastasis, which highlights secreted miR-103 as a potential therapeutic target and predictive marker for HCC metastasis.
